DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20174788

Pharmacoeconomic assessment and comparing efficacy between cetirizine, levocetirizine, loratadine and fexofenadine in allergic rhinitis patients

Ganesh S. Pentewar, Ranjit J. Wagh, Aparna S. Chincholkar

Abstract


Background: A successful treatment of allergic rhinitis is considered not only as relief from sneezing, itching, rhinorrhoea, congestion but also as the functional impact on the patient’s daily life. The cost of treating allergic rhinitis and indirect costs related to loss of workplace productivity are substantial.

Methods: The present study was single centered, open label, randomized, four Arm, parallel-group, comparative clinical study between orally administered Cetirizine, Levocetirizine, Loratadine and Fexofenatidine in patients with allergic rhinitis conducted at MIMER Medical college and Dr. Bhausaheb Sardesai hospital in rural Maval Taluka in Pune district of Maharashtra State.

Results: Total Nasal Symptom Score differs significantly for all the treatment groups. Subsequent pairwise contrasts using a Bonferroni adjustment reveals maximum reduction of symptoms in Levocetirizine group. Cost effectiveness ratio was effective for Levocetirizine followed by Cetirizine, Loratadine, and Fexofenadine.

Conclusions: From the analysis of results, the study shows that both Levocetirizine and Cetirizine control the symptoms of allergic rhinitis better as compared to Loratadine and Fexofenadine but Levocetirizine was a better choice in comparison to others due to its cost effectiveness.


Keywords


Allergic rhinitis, Cetirizine, Fexofenadine, Loratadine, Levocetirizine, Pharmacoeconomic assessment, Total nasal symptom score

Full Text:

PDF

References


Shah A, Pawankar R. Allergic rhinitis and co-morbid asthma: perspective from India-ARIA Asia-Pacific Workshop report. Asian Pacific journal of allergy and immunology. 2009 Mar 1;27(1):71.

Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA). Allergy. 2008 Apr 1;63(s86):8-160.

Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy. 2005 Mar 1;60(3):350-3.

Scarupa MD, Michael A. Kaliner Inflammatory Nature of Allergic Rhinitis: Pathophysiology. Medscape Allergy & Immunology. 2006;6(1).

Hay JW, Kaliner MA. Costs of second-generation antihistamines in the treatment of allergic rhinitis: US perspective. 2009 Jun; 25(6):1421-31.

Hay JW, Leahy M. Cost and Utilization Impacts of Oral Antihistamines in the California Medi-Cal Program. Value in Health. 2005;8:506-16.

Kulkarni U, Dalvi K, Moghe VV, Deshmukh YA. Pharmacoeconomics: An emerging branch in health sciences for decision making. African Journal of Pharmacy and Pharmacology. 2009 Aug 31;3(8):362-7.

Goodman and Gilman’s. The Pharmacological Basis of Therapeutics, 12th Ed. China: Mc Graw Hill companies; 2011:920.

Maiti R, Jaida J, Rahman J, Gaddam R, Palani A. Olopatadine hydrochloride and rupatadine fumarate in seasonal allergic rhinitis: A comparative study of efficacy and safety. Journal of pharmacology & pharmacotherapeutics. 2011 Oct;2(4):270.

Newby D, Hill S. Use of pharmacoeconomics in prescribing research. Part 2: cost minimization analysis - when are two therapies equal? J of Clinical Pharmacy and Therapeutics. 2003;28:145-50.

Lopert R, Lang DL, Hill SR. Use of pharmacoeconomics in prescribing research. Part 3: cost‐effectiveness analysis–a technique for decision‐making at the margin. Journal of clinical pharmacy and therapeutics. 2003 Jun 1;28(3):243-9.

Mösges R, König V, Köberlein J. The effectiveness of modern antihistamines for treatment of allergic rhinitis-an IPD meta-analysis of 140,853 patients. Allergology International. 2013;62(2):215-22.

Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clinical & Experimental Allergy. 2004 Jun 1;34(6):958-64.

Horak F, Zieglmayer PU, Zieglmayer R, Kavina A, Lemell P. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. British journal of clinical pharmacology. 2005 Jul 1;60(1):24-31.

Stübner P, Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit–the Vienna Challenge Chamber (VCC). Current medical research and opinion. 2004 Jun 1;20(6):891-902.

Dubuske LM, Seal B, Brown MC. Pharmacoeconomics of levocetirizine in allergic rhinitis and chronic idiopathic urticaria: considerations for the USA. Expert Rev Pharmacoecon Outcomes Res. 2008 Jun;8(3):233-41.

Rogkakou A, Villa E, Garelli V, Canonica GW. Persistent allergic rhinitis and the XPERT study. World Allergy Organization Journal. 2011 Mar 15;4(3):S32.

Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J, et al. XPERT Study Group. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. Journal of allergy and clinical immunology. 2004 Oct 31;114(4):838-44.

Lee CF, Sun HL, Lu KH, Ku MS, Lue KH. The comparison of cetirizine, levocetirizine and placebo for the treatment of childhood perennial allergic rhinitis. 2009;20(5):493-9.